What are the indications for cimepilimab in non-small cell lung cancer?

Cemiplimab-rwlc (cemiplimab-rwlc), as an innovative immunotherapy drug, has attracted much attention for its application in the treatment of non-small cell lung cancer (NSCLC). In recent years, cimepilimab has made significant progress in the treatment of NSCLC and gained specific indications.

The main mechanism of action of cimepilimab is to help the body recognize and attack cancer cells by strengthening the patient's own immune system. This drug blocks the interaction between the PD-1 receptor and its ligand PD-L1, thereby restoring the anti-tumor activity of T cells and allowing the immune system to fight tumors more effectively.

Specifically, cimepilimab has been approved for the first-line treatment of adult patients with non-small cell lung cancer without EGFR, ALK or ROS1 abnormalities, in combination with platinum-based chemotherapy, in locally advanced (patients not suitable for surgical resection or definitive chemoradiotherapy) or metastatic disease. In addition, it is approved as a single agent for the first-line treatment of adult patients with non-small cell lung cancer whose tumors have high PD-L1 expression (Tumor Proportion Score TPS ≥ 50%) and no EGFR, ALK or ROS1 abnormalities, also in locally advanced or metastatic settings.

The approval of this indication provides new treatment options for patients with specific types of non-small cell lung cancer. However, as a prescription drug, cimepilimab must be used under the guidance of a doctor. Patients should strictly follow the doctor's instructions when taking medications and undergo regular examinations to ensure the safety and effectiveness of the medications.

It is reported that a box of the European version of Cimepril monoclonal antibody costs about more than 40,000 yuan. For patients, it is important to purchase this drug through formal channels to ensure the quality and efficacy of the drug.

In short, the application of cimepilimab in the treatment of non-small cell lung cancer has brought new hope to patients, but rational drug use and formal purchase channels are equally important.